• Jubilant Pharmova reported an increase in consolidated net profit to ₹481.8 crore, largely due to the gain from the sale of its investment in SOFIE Biosciences Inc. 
  • Despite a slight 1.53% decline in quarterly revenue to ₹1,731.7 crore, Jubilant Pharmova's profit soared by 922.7%, showcasing strong growth momentum. 
  • The company has delivered a 33.28% Year-to-Date return and continues to attract investor interest with a market cap of ₹11512.1 Cr.

Jubilant Pharmavo, a pharmaceutical company that handles everything from research to sales, announced a significant increase in its total profit to ₹481.8 crore. This boost was mainly due to the profit gained from selling its investment in a related company, SOFIE Biosciences Inc. USA.

The total revenue from operations amounted to ₹1,731.7 crore, up from ₹1,586.9 crore last year. Compared to the previous quarter, revenue saw a slight decrease of 1.53%, but profits surged by 922.7%, showing strong growth.

In the first quarter of the current fiscal year, exceptional items included a net income of ₹669.2 crore from the sale of investment in SOFIE, expenses of ₹91.6 crore due to the closure of a solid dosage formulation facility in Salisbury, Maryland, USA, a provision of ₹95.3 crore for slow-moving inventory in the solid dosage formulation business, and litigation costs amounting to ₹50 crore, among others.

Furthermore, investors have shown confidence in Jubilant Pharmova, with returns of 0.15% over the past week, 31.06% over the last 6 months, and a notable 33.28% Year-to-Date return. The company currently boasts a market capitalization of ₹11,512.1 crore, with its 52-week high and low at ₹780.3 and ₹318.75 respectively. 

Analysts covering the company have all given a Strong Buy rating, with the consensus recommendation as of July 20, 2024, reaffirming a Strong Buy outlook for the company's future. During the quarter, Jubilant Pharmova reported that revenue from its radiopharmaceuticals segment increased by 28% year-on-year to ₹262 crore, and revenue from allergy immunotherapy grew by 11% to ₹168 crore.

Meanwhile, on July 22, Jubilant Pharmova's share price dropped nearly 3% in early trading following news that the company's Canada facility had received a 'voluntary action indicated' (VAI) status from the US Food and Drug Administration (US FDA).

Edited by Harshajit Sarmah